Partnership Opportunities
2024 is poised to be an inflection point for viral vector-based drug developers, focusing primarily on moving their clinical asset through the pipeline into IND filing and commercialization. They are looking for the long-term partners who can help them embark on this journey, with quality, costs, and capabilities in mind for successful IND submission and patient affordability.
With viral vector process development being one of the most costly and challenging step, they are seeking partners who can offer:
Novel equipment with compatibility consideration
CDMOs with the technical capabilities, capacity, quality compliance, and infrastructure
PAT and monitoring software to ensure real time quality control
Assay and formulation experts to maximize stability and confidence in product release
The likes of Lonza, TEKNOVA, ChromaTan, Genezen, and SGS partnered to leverage this forum to connect with the right, and selected decision makers from UCB, AstraZeneca, Sarepta, and more. Partners of this premium summit elevated their brand and drove collaboration through:
Thought leadership case studies and hosting a panel discussion
Tech demo and product guide
Private lunch for a hands-on workshop
Get in touch today and we can explore further on how we can support you to meet your future commercial goals and position your organization as the trusted viral vector innovator.
2024 Partners:
Experts Need Your Help With:
- Facilities to tackle scalability challenges and boost manufacturing volumes
- Formulation and raw material providers to aid with cell line engineering and transfection reagents
- Analytical assays to help provide appropriate potency assays to measure efficiency and maximize titres
Why Partner?
Connect with industry experts across upstream and downstream process development, viral vector technology and CMC to position yourself at the forefront of the rapidly evolving viral vector market
Showcase your expertise by presenting your products and services to a targeted audience of viral vector specialists, biopharma professionals and key decisions markers
Learn of the biggest challenges being faced in the viral vector industry from the expert speaker faculty to identify gaps in the market and inform you commercial strategy for 2024 and beyond
GET IN TOUCH
Who Attendees Met?
